Ellis A - Search Results

1

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.

Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, et al. Kantarjian HM, et al. Among authors: ellis a. Blood. 1993 Mar 1;81(5):1146-51. Blood. 1993. PMID: 8382970 Free article. Clinical Trial.

2

Topotecan in chronic lymphocytic leukemia.

O'Brien S, Kantarjian H, Ellis A, Zwelling L, Estey E, Keating M. O'Brien S, et al. Among authors: ellis a. Cancer. 1995 Mar 1;75(5):1104-8. doi: 10.1002/1097-0142(19950301)75:5<1104::aid-cncr2820750509>3.0.co;2-b. Cancer. 1995. PMID: 7850708 Clinical Trial.

3

Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.

Ellis AL, Nowak B, Plunkett W, Zwelling LA. Ellis AL, et al. Cancer Chemother Pharmacol. 1994;34(3):249-56. doi: 10.1007/BF00685085. Cancer Chemother Pharmacol. 1994. PMID: 8004759

4

Time course of phorbol-12-myristate-13-acetate (PMA)-induced down-regulation of topoisomerase II in human leukemia cells.

Ellis AL, Zwelling LA. Ellis AL, et al. Biochem Pharmacol. 1994 Nov 1;48(9):1842-5. doi: 10.1016/0006-2952(94)90472-3. Biochem Pharmacol. 1994. PMID: 7980655

5

Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.

Abbruzzese JL, Madden T, Sugarman SM, Ellis AL, Loughlin S, Hess KR, Newman RA, Zwelling LA, Raber MN. Abbruzzese JL, et al. Among authors: ellis al. Clin Cancer Res. 1996 Sep;2(9):1489-97. Clin Cancer Res. 1996. PMID: 9816325 Clinical Trial.

6

Phorbol regulation of topoisomerases I and II in human leukemia cells. Studies in an additional cell pair sensitive or resistant to phorbol-induced differentiation.

Ellis AL, Altschuler E, Bales E, Hinds M, Mayes J, Soares L, Zipf TF, Zwelling LA. Ellis AL, et al. Biochem Pharmacol. 1994 Jan 20;47(2):387-96. doi: 10.1016/0006-2952(94)90030-2. Biochem Pharmacol. 1994. PMID: 8304982

7

Components of intrinsic drug resistance in the rat hepatoma.

Ellis AL, Munger CE, Bunch RT, Woods KE, Randolph JK, Boise L, Swerdlow PS, Zwelling LA, Hinds M, Yanovich S, et al. Ellis AL, et al. Biochem Pharmacol. 1992 Jan 22;43(2):331-42. doi: 10.1016/0006-2952(92)90296-u. Biochem Pharmacol. 1992. PMID: 1310853

8

What I say is not what I do: Gender differences in the home mathematics environment.

Varnell S, Ehrman P, Kumar SC, Sandel J, Ellis A, Purpura DJ. Varnell S, et al. Among authors: ellis a. Dev Psychol. 2025 Jan 6. doi: 10.1037/dev0001901. Online ahead of print. Dev Psychol. 2025. PMID: 39760731

9

Allergic rhinitis.

Rosenfield L, Keith PK, Quirt J, Small P, Ellis AK. Rosenfield L, et al. Among authors: ellis ak. Allergy Asthma Clin Immunol. 2024 Dec 27;20(Suppl 3):74. doi: 10.1186/s13223-024-00923-6. Allergy Asthma Clin Immunol. 2024. PMID: 39731198 Free PMC article. Review.

10

Impact of social determinants of health on the outcomes of Latin American children with Multisystem Inflammatory Syndrome (MIS-C).

Buonsenso D, Camporesi A, Sawaya C, Ulloa-Gutierrez R, Faugier-Fuentes E, Dueñas L, Paternina-de la Ossa RA, Llamas-Guillén BA, Gámez-González LB, Gálvez-Rafael N, Gatica A, Saltigeral-Simental P, Cuatecontzi-Romero A, Almeida FJ, Cuan S, Zapata-Yarlequé EH, Beltrán S, Reina-Bautista E, Collia A, Ivankovich-Escoto G, Fernández-Sarmiento J, Tremoulet AH; REKAMLATINA‐3 MIS‐C Study Group Investigators. Buonsenso D, et al. Pediatr Pulmonol. 2024 Dec 26. doi: 10.1002/ppul.27313. Online ahead of print. Pediatr Pulmonol. 2024. PMID: 39723622

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,781 results

Search Page

Filters